Indications: Treatment of acute pain;primary dysmenorrhea.Nimesulide should only be used as a second-line drug.The decision to prescribe a drug should be made on the basis of an assessment of all risks for a particular patient.
Contraindications:
Hypersensitivity to Nimesulidе or to any component of the drug; hyperergic reactions that have occurred in the past (bronchospasm, rhinitis, urticaria) in connection with the use of acetylsalicylic acid or other nonsteroidal anti-inflammatory drugs (NSAIDs); hepatotoxic reactions to nimesulide, which have occurred in the past; stomach and duodenal ulcer in the acute phase; recurrent ulcers or bleeding in the digestive tract; a history of gastrointestinal bleeding associated with previous use of non-steroidal anti-inflammatory drugs; cerebrovascular bleeding; bleeding accompanying other diseases; severe blood clotting disorders; severe heart failure; severe renal failure (creatinine clearance <30 ml / min); severe liver failure; Fever and / or flu-like symptoms suspicion of acute surgical pathology. Alcoholism and drug addiction. Do not use concomitantly with other drugs that may cause hepatotoxic reactions. Children under 12 years old. Third trimester of pregnancy and lactation. Interaction with other medicinal products and other types of interactions.
Method of administration and dosage:
Prescribe the Nimesulidе after careful assessment of the benefit / risk ratio. Use the lowest effective dose for a short time. The maximum duration of the course of treatment with Nimesulidе is 15 days. Adults and children from 12 years of age: the drug should be taken 1 tablet (100 mg) 2 times a day (daily dose – 200 mg). Elderly patients: dose adjustment is not required. Patients with impaired renal function: for patients with mild to moderate renal failure (creatinine clearance 30–80 ml / min), dose adjustment is not required. Nimesulide should be taken orally after meals and with a sufficient amount of liquid. In severe renal failure (creatinine clearance <30 ml / min), the use of the drug is contraindicated. Patients with impaired liver function. The use of nimesulide for the treatment of patients with impaired liver function is contraindicated (see section “Contraindications”).
Application features:
Nimesulide should only be used as a second-line drug.The decision on the appointment of Nimesulidе must be made on the basis of an assessment of all risks for a particular patient.Undesirable side effects can be minimized by taking the lowest effective dose for the shortest period necessary to control the symptoms of the disease.In the absence of effective treatment (reduction of symptoms of the disease), drug therapy should be discontinued.
When using the Nimesulidе, there have been reports of cases of severe liver reactions, including fatal ones. Patients who have symptoms similar to those of liver damage (for example: anorexia, nausea, vomiting, abdominal pain, fatigue, dark urine) and patients who have abnormal liver function tests should stop using the drug … Reappointment of nimesulide in such patients is contraindicated. After short-term use of the drug, reversible liver damage was observed in most cases.
Gastrointestinal bleeding or ulcer / perforation can develop at any time with the use of the drug with or without warning symptoms, with or without a history of gastrointestinal diseases.If gastrointestinal bleeding or ulcers occur, the drug should be discontinued.
An ulcer, bleeding or perforation in the digestive tract can threaten the patient’s life, especially if there is evidence in the anamnesis that similar phenomena have occurred in the patient when using any other NSAIDs (no statute of limitations).The risk of such events increases with an increase in the dose of NSAIDs in patients with a history of ulcers in the digestive tract, especially complicated by bleeding or perforation, as well as in elderly patients.In such patients, treatment should be started with the lowest possible effective dose.
Shelf life:3 years.
Storage conditions: Keep out of the reach of children in the original packaging at a temperature not exceeding 25 ° C.
